论文部分内容阅读
目的探讨沐舒坦氧气驱动雾化吸入佐治喘息性支气管炎的疗效。方法对本院于2003-04~2004-12共86例喘息性支气管炎患儿,随机分成两组进行研究,比较沐舒坦氧气驱动雾化吸入与常规雾化吸入的效果。结果沐舒坦组住院天数平均为8.4d,常规组为11.2d,两者有显著差异有统计学意义(P<0.05)。肺部痰鸣音消失时间:沐舒坦组平均为5.1d,而常规组为8.4d,(P<0.05)。两者有显著差异,亦有统计学意义。〗结论沐舒坦氧气驱动雾化吸入治疗喘息性支气管炎是一种安全、高效、且副作用少、操作简单、经济实用、交叉感染少的有效方法。
Objective To investigate the curative effect of mucosolvan oxygen driven aerosol inhalation on asthmatic asthmatic bronchitis. Methods A total of 86 asthmatic bronchitis patients from 2003-04 to 2004-12 in our hospital were randomly divided into two groups to study the effects of ambroxol on aerosol inhalation and conventional inhalation. Results The average duration of stay in mucosolvan group was 8.4 days, and that in routine group was 11.2 days. There was a significant difference between the two groups (P <0.05). Lung phlegm disappeared time: mucosolvan group averaged 5.1d, while the conventional group was 8.4d, (P <0.05). There are significant differences between the two, but also statistically significant. Conclusion Mucosolvan inhalation aerosol inhalation treatment of asthmatic bronchitis is a safe, efficient and less side effects, simple, economical and practical, less effective cross-infection method.